Evidence map›Paper›PMID 34983646›Full record

Trial reportBMC research notes2022

Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.

Halima Bello-Manga, Lawal Haliru, Abdulkadir M Tabari, Bilkisu Farouk, Aisha Suleiman, Gloria Y Bahago, Abdulrasheed M Sani, Ana A Bauman, Michael R DeBaun, Allison A King

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Halima Bello-MangaDepartment of Hematology and Blood Transfusion, Barau Dikko Teaching Hospital/Kaduna State University, Lafia Road, Kaduna, Nigeria. mamanzara@yahoo.co.uk.ORCID http://orcid.org/0000-0001-9993-4548
Lawal HaliruDepartment of Pediatrics, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Abdulkadir M TabariDepartment of Radiology, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Bilkisu FaroukDepartment of Radiology, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Aisha SuleimanDepartment of Radiology, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Gloria Y BahagoDepartment of Nursing Services, Hematology Unit, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Abdulrasheed M SaniResearch Office, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria.
Ana A BaumanDepartment of Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Michael R DeBaunDepartment of Pediatrics, Division of Pediatric Neurology, Vanderbilt University of Medicine, Nashville, Tennessee, USA.
Allison A KingDepartment of Pediatrics, Division of Hematology and Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Kaduna State University · NGWashington University in St. Louis · USVanderbilt University · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
PHARMacist and Community Health Support to Optimize Medications After Trauma Surgery (PHARM-C)P50MH122351 · NIMH · WASHINGTON UNIVERSITY · PI Michael Simon Avidan, Eric J Lenze · 2021 to 2026
$10.8M
Washington University Implementation Science Center for Cancer Control (WU-ISCCC)P50CA244431 · NCI · WASHINGTON UNIVERSITY · PI BROWNSON, ROSS C, COLDITZ, GRAHAM A. · 2019 to 2023
$8.0M
Primary prevention of stroke in children with SCD in Sub-Saharan Africa IIR01NS094041 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ABDULLAHI, SHEHU UMAR, ALIYU, MUKTAR HASSAN · 2015 to 2019
$5.4M
(SCANS) Sickle Cell Anemia Neurodevelopmental Screening - Mentoring and Research in Patient Oriented ResearchK24HL148305 · NHLBI · WASHINGTON UNIVERSITY · PI Allison A King · 2019 to 2026
$706k
Developing T4 Translational Research Capacity for Control of Hypertension in RwandaU24HL136790 · NHLBI · RASD RWANDA · PI MUTIMURA, EUGENE · 2017 to 2020
$596k
Mentoring in Patient-Oriented Research focused on Neurological Complications of Sickle Cell DiseaseK24HL147017 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JORDAN, LORI CHAFFIN · 2019 to 2023
$547k
Primary Prevention of Stroke in Children with Sickle Cell Anaemia in Nigeria: Community vs Teaching HospitalK43TW011583 · FIC · BARAU DIKKO TEACHING HOSPITAL/ KADUNA STATE UNIVERSITY · PI BELLO-MANGA, HALIMA · 2020 to 2024
$425k
Primary Prevention of Strokes in Nigerian Children with Sickle Cell DiseaseR21NS080639 · NINDS · VANDERBILT UNIVERSITY · PI ALIYU, MUKTAR HASSAN, DEBAUN, MICHAEL R. · 2012 to 2013
$282k
FIC NIH HHS K43 TW011583FIC NIH HHS K43TW011583NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1TR002345NCI NIH HHS P50 CA-244431NCI NIH HHS P50 CA244431NHLBI NIH HHS 1K24 HL148305NHLBI NIH HHS 5U24HL136790NHLBI NIH HHS K24 HL147017NHLBI NIH HHS K24 HL148305NHLBI NIH HHS U24 HL136790NIMH NIH HHS P50 MH122351NINDS NIH HHS 1R01NS094041NINDS NIH HHS R01 NS094041NINDS NIH HHS R21 NS080639
6 · The paper itself

Abstract

objectivesEvidence-based practice for stroke prevention in high-income countries involves screening for abnormal transcranial Doppler (TCD) velocity and initiating regular blood transfusions for at least 1 year, followed by treatment with hydroxyurea. This practice has not been transferred to low-resource settings like Nigeria, the country with the highest global population density of SCD. Following a multi-center randomized controlled trial among children with SCA in northern Nigeria, screening for stroke and initiation of hydroxyurea was established as standard of care at the clinical trial sites and other locations. We aim to describe the critical steps we took in translating research into practice for stroke prevention in SCA in Nigeria. Guided by the PRISM framework, we describe how we translated results from a randomized controlled trial for primary prevention of stroke in children with sickle cell anemia into usual care for children with SCA in Kaduna, Nigeria.

resultsFindings from this study demonstrate the importance of organizational support and stakeholder involvement from the onset of a clinical trial. Having the dual objective of conducting an efficacy trial while simultaneously focusing on strategies for future implementation can significantly decrease the lag time between discovery and routine practice.

Indexed as

Anemia, Sickle CellStrokeAntisickling AgentsHumansHydroxyureaNigeriaUltrasonography, Doppler, TranscranialAntisickling AgentsHydroxyureaPRISMSickle cell diseaseStroke

Identifiers

PMID34983646
PMCPMC8725461
OpenAlexW4205412059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.